Table 1.
Patient characteristics.
| Variables | |
|---|---|
| Age (year, median, IQR) | 74 (63–82) |
| ECOG Performance Status (number, %) | |
| 0 | 31 (48.4) |
| 1 | 18 (28.1) |
| 2 | 8 (12.5) |
| 3 | 6 (9.4) |
| 4 | 1 (1.6) |
| Clinical T stage (number, %) | |
| Tis | 1 (1.6) |
| T1 | 26 (40.6) |
| T2 | 20 (31.3) |
| T3 | 14 (21.9) |
| T4 | 2 (3.1) |
| Clinical N stage (number, %) | |
| 0 | 38 (59.4) |
| 1 | 9 (14.1) |
| 2 | 8 (12.5) |
| 3 | 9 (14.1) |
| Clinical stage (number, %) | |
| Is | 1 (1.6) |
| 1 | 21 (32.8) |
| 2 | 14 (21.9) |
| 3 | 17 (26.6) |
| 4 | 11 (17.6) |
| Treatment modality (number, %) | |
| Surgery only | 51 (79.7) |
| Surgery and chemotherapy | 6 (9.4) |
| Radiation only | 1 (1.6) |
| Best supportive care | 6 (15.6) |
| Albumin (g/dL, median, IQR) | 4.2 (3.7–4.4) |
| Hemoglobin (g/dL, median, IQR) | 13.2 (11.4–14.8) |
| C-reactive protein (mg/dL, median, IQR) | 0.21 (0.06–1.28) |
| Tumor size (mm, median, IQR) | 30 (20–40) |
| Number of LNM (number, median, IQR) | 2 (1–6) |
| NLR (median, IQR) | 3.05 (2.03–4.96) |
| PLR (median, IQR) | 148 (105–228) |
| Pretreatment SCC (ng/mL, median, IQR) | 1.65 (1.23–4.18) |
| Follow-up period (months, median, IQR) | 26.0 (9.0–61.3) |
IQR: interquartile range; ECOG: The Eastern Cooperative Oncology Group; LNM: lymph node metastasis; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; SCC: squamous cell carcinoma antigen.